Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 6/20 | 0.44 |
| ▸ | RARB | P10826 | 6/20 | 0.44 |
| ▸ | RARG | P13631 | 5/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | RXRA | P19793 | 7/20 | 0.33 |
| ▸ | HNF4A | P41235 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 2/20 | 0.31 |
| ▸ | RXRG | P48443 | 2/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5047362 | 1.00 | RARA (0.44) | RARARARBRARGPTPN1RXRA | |
| SCHEMBL5047355 | 1.00 | RARA (0.44) | RARARARBRARGPTPN1RXRA | |
| SCHEMBL5050810 | 0.93 | RARA (0.43) | RARARARBRARGPTPN1RXRA | |
| SCHEMBL5050811 | 0.93 | RARA (0.43) | RARARARBRARGPTPN1RXRA | |
| SCHEMBL5050808 | 0.93 | RARA (0.43) | RARARARBRARGPTPN1RXRA | |
| SCHEMBL5043983 | 0.91 | RARA (0.42) | RARARARBRARGPTPN1RXRA | |
| SCHEMBL5043987 | 0.91 | RARA (0.42) | RARARARBRARGPTPN1RXRA | |
| SCHEMBL5043993 | 0.91 | RARA (0.42) | RARARARBRARGPTPN1RXRA | |
| SCHEMBL5048378 | 0.88 | RARB (0.58) | RARARARBRARGRXRAHNF4A | |
| SCHEMBL5048382 | 0.88 | RARB (0.58) | RARARARBRARGRXRAHNF4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326803-B2 | Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-02-05 | — | — | US | claimed |
| US-20050148670-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-07-07 | — | — | US | claimed |
| US-7326803-B2 | Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-02-05 | — | — | US | disclosed |
| US-20050148670-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148670-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | RARA, RARB, RARG | RARA 1/4885RARB 2/4885RARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.